205
Participants
Start Date
May 5, 2022
Primary Completion Date
August 2, 2023
Study Completion Date
February 21, 2024
Izokibep
"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
Placebo to izokibep
"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
Clinical Research Site, Budapest
Clinical Research Site, Debrecen
Clinical Research Site, Barcelona
Clinical Research Site, Schwerin
Clinical Research Site, Kiel
Clinical Research Site, Kiel
Clinical Research Site, Sandy Springs
Clinical Research Site, Savannah
Clinical Research Site, Ocala
Clinical Research Site, Pontevedra
Clinical Research Site, Bochum
Clinical Research Site, Plainfield
Clinical Research Site, Indianapolis
Clinical Research Site, Manises
Clinical Research Site, Bad Bentheim
Clinical Research Site, Baton Rouge
Clinical Research Site, Webster
Clinical Research Site, Los Angeles
Clinical Research Site, Portland
Clinical Research Site, Birmingham
Clinical Research Site, Encino
Clinical Research Site, Fountain Valley
Clinical Research Site, Los Angeles
Clinical Research Site, Tampa
Clinical Research Site, Rolling Meadows
Clinical Research Site, Murray
Clinical Research Site, New York
Clinical Research Site, Mason
Clinical Research Site, Philadelphia
Clinical Research Site, Pittsburgh
Clinical Research Site, London
Clinical Research Site, Markham
Clinical Research Site, Waterloo
Clinical Research Site, Québec
Clinical Research Site, Saskatoon
Clinical Research Site, Krakow
Clinical Research Site, Krakow
Clinical Research Site, Wroclaw
Clinical Research Site, Wroclaw
Clinical Research Site, Bialystok
Clinical Research Site, Katowice
Clinical Research Site, Lublin
Clinical Research Site, Szczecin
Clinical Research Site, Palma de Mallorca
ACELYRIN Inc.
INDUSTRY